MUSCAT: Pharmaceutical giant AstraZeneca has “voluntarily paused” a clinical trial of its coronavirus vaccine after a volunteer developed an unexplained illness.
The company, which is developing the drug alongside the University of Oxford in the UK, is a frontrunner in the global race for a COVID-19 vaccine.
“As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee,” a spokesperson said.
Read More
- Oman, Iran agree framework for safe shipping corridor through Strait of Hormuz
- Thunderstorms, strong downdraft winds sweep parts of Oman
- Saudi Crown Prince sends written message to His Majesty Sultan Haitham
- Oman FM arrives in Tehran, discusses safe passage of ships through Strait of Hormuz
- CPA seizes 1,668 soft drinks, 177 expired juice cans in Oman
“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”
“We are working to expedite the review of the single event to minimise any potential impact on the trial timeline,” the spokesperson added.
